Products
Online Inquiry
AT13148
Cat. No.:
0225LY-0805
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
AT13148 is an orally active, ATP-competitive inhibitor targeting multiple AGC kinases, including ROCKI/II, PKA, p70S6K, and Akt1/2/3.
Synonym:
1056901-62-2; (S)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-amino-1-(4-chlorophenyl)ethanol; (1S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol; (+)-(S)-2-Amino-1-(4-chlorophenyl)-1-(4-(1H-pyrazol-4-yl)phenyl)ethanol; Benzenemethanol, alpha-(aminomethyl)-alpha-(4-chlorophenyl)-4-(1H-pyrazol-4-yl)-, (alphaS)-; (S)-1-(4-(1H-pyrazol-4-yl)phenyl)-2-amino-1-(4-chlorophenyl)ethan-1-ol
CAS No.:
1056901-62-2
Compound CID:
24905401
Formula:
C17H16ClN3
Formula Weight:
313.78
Specification
Targets&IC50:
ROCK1: 6 nM; ROCK2: 4 nM; PKA: 3 nM; p70 S6K: 8 nM; Akt1: 38 nM
Relative Density:
1.328 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
AT13148 can be used in cancer pharmacology to study the multi-isotype inhibition of the AKT kinase family.
Library Information
Target:
ROCK; SGK; Akt; PKA; S6 Kinase
Receptor:
Akt1; Akt2; Akt3; p70 S6K; PKA; RSK; ROCK; ROCK1; ROCK2; RSK1; SGK3
Pathways:
MAPK; Cell cycle/Checkpoint; Metabolism; Tyrosine kinase/adaptors; PI3K/Akt/mTOR signaling; Cytoskeletal signaling; Stem cell regulation
Plate Number:
AOCL-11
Plate Location:
d4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
58 mg/mL; 184.84 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.491
HBA_Count:
1
HBD_Count:
2
Rotatable Bond:
4
